Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies
PCSK9单克隆抗体治疗对心血管风险极高患者的治疗持续性、降脂效果和3年临床结局的影响
期刊:Clinical Research in Cardiology
影响因子:3.7
doi:10.1007/s00392-025-02719-z
Parhofer, Klaus G; Pittrow, David; Birkenfeld, Andreas L; Fraass, Uwe; Hohenstein, Bernd; Siegert, Carsten; Klotsche, Jens; Steinhagen-Thiessen, Elisabeth; Dexl, Stefan; Schettler, Volker J J; Laufs, Ulrich